An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002.
Phase of Trial: Phase II
Latest Information Update: 28 Feb 2019
Price : $35 *
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors ForSight VISION5
- 08 Nov 2017 According to an Allergan media release, pooled results from this and another open-label extension trial will be presented at the annual American Academy of Ophthalmology (AAO) meeting.
- 01 Feb 2016 Status changed from active, no longer recruiting to completed.
- 12 Aug 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials .gov record.